Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DS 9001

Next Previous
Drug Profile

DS 9001

Alternative Names: Anti-PCSK9-anticalin-albumod; DS-9001

Latest Information Update: 17 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pieris Pharmaceuticals
  • Developer Daiichi Sankyo Company
  • Class Antihyperlipidaemics; Proteins
  • Mechanism of Action Immunomodulators; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dyslipidaemias

Most Recent Events

  • 13 Dec 2024 Pieris Pharmaceuticals has merged with Palvella Therapeutics to form Palvella Therapeutics
  • 31 Jan 2017 Discontinued - Phase-I for Dyslipidaemias due to unfavourable study results in USA (SC) (Daiichi Sankyo pipeline, May 2017)
  • 01 Dec 2015 Phase-I clinical trials in Dyslipidaemias in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top